Reactions Weekly

, Volume 1734, Issue 1, pp 386–386 | Cite as


Diarrhoea and development of osimertinib resistance: 4 case reports
Case report


  1. Stratmann JA, et al. Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology 144: 2457-2463, No. 12, Dec 2018. Available from: URL: Available from: URL: - GermanyCrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations